Cat. No.: HY-172920

Wnt/β-catenin-IN-6

Customer Review

Based on 1 Customer Validation

Wnt/β-catenin-IN-6 is an orally active Wnt/β-catenin pathway inhibitor. Wnt/β-catenin-IN-6 blocks the AKT/GSK-3β/β-catenin signaling pathway, leading to reduced expression of Wnt target genes (c-Myc, c-Jun). Wnt/β-catenin-IN-6 reduces COX2 expression and IL-8 levels, highlighting its dual anti-inflammatory and antitumor effects. Wnt/β-catenin-IN-6 can induce apoptosis. Wnt/β-catenin-IN-6 serves as a tool for non-small cell lung cancer (NSCLC) research.

For research use only. We do not sell to patients.

Purity: 98.34%
Formula: C₂₅H₂₂N₄O₃
Molecular Weight:426.47

Storage:

Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month

Wnt/β-catenin-IN-6 Chemical Structure

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Antibody-Drug Conjugates

One-stop solution for XDC (ADC/PDC/RDC/ApDC/FDC/ISAC/VDC/SMDC)

Biological Activity
- Description
- IC₅₀ & Target
- In Vitro
- In Vivo
Chemical Information
Solvent & Solubility
- In Vitro
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

IC₅₀ & Target^[1]

COX-2

EGFR

GSK-3β

ERK

IL-8

Akt

JNK

All Wnt Isoforms :

All EGFR Isoforms :

All ERK Isoforms :

All COX Isoforms :

All Akt Isoforms :

All GSK-3 Isoforms :

All Interleukin Related Isoforms :

All JNK Isoforms :

In Vitro

Wnt/β-catenin-IN-6 (Compound B10) (72 h), demonstrates potent cytotoxic activity toward human non-small cell lung cancer cell line A549 (IC₅₀ = 1.28 μM), with IC₅₀ values of 3.74, 3.22, 5.68 μM in SKOV3, MDAMB-231, BEAS-2B cells respectively^[1].
Wnt/β-catenin-IN-6 (2, 4 μM, 48 h) shows potent antiproliferative effect by suppressing the EGFR/Erk signaling pathway in A549 cells^[1].
Wnt/β-catenin-IN-6 (4 μM, 72 h) induces only 10 % apoptotic response, with no significant difference from the control group in A549 cells^[1].
Wnt/β-catenin-IN-6 (2, 4 μM, 48 h) inhibits the Wnt/β-catenin signaling pathway in A549 cells via the AKT/GSK-3β/β-catenin axis^[1].
Wnt/β-catenin-IN-6 (2, 4 μM, 48 h) downregulates the IL-8 mRNA expression in A549 cells as well as the expression of c-Myc and c-Jun, suggesting the inflammation-suppression effect^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[1]

Cell Line:

A549 cells
Concentration:

2, 4 μM
Incubation Time:

48 h
Result:

Reduced the phosphorylation levels of EGFR and Erk in A549 cells under basal conditions (without exogenous EGF).
Led to a significant decrease in the expression of phosphorylated EGFR in the presence of EGF, while the inhibition of Erk phosphorylation was less pronounced.

Western Blot Analysis^[1]

Cell Line:

A549 cells
Concentration:

2, 4 μM
Incubation Time:

48 h
Result:

Reduced significantly COX2 expression in A549 cells.
Led to a significant reduction in p-AKT levels and the p-AKT to AKT ratio.
Decreased the level of p-GSK-3β dramatically, as well as the ratio of p-GSK-3β to GSK-3β, which in turn led to the downregulation of active (non-phosphorylated) β-catenin.

Real Time qPCR^[1]

Cell Line:

A549 cells
Concentration:

2, 4 μM
Incubation Time:

48 h
Result:

Downregulated the IL-8 mRNA expression in A549 cells, suggesting the inflammation-suppression effect.
Downregulated the expression of c-Myc and c-Jun.

In Vivo

Wnt/β-catenin-IN-6 (compound B10) (25 mg/kg, i.g., every other day) possesses significant anti-NSCLC activity and favorable biosafety in an A549 xenograft model established in male BALB/C nude mice^[1].
Wnt/β-catenin-IN-6 (12.5-50 mg/kg, i.g., once) exhibits no observable toxicity in ICR mice at doses up to 50 mg/kg^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

An A549 xenograft model established in male BALB/C nude mice (6 weeks)^[1]
Dosage:

25 mg/kg
Administration:

intragastric gavage (i.g.) every other day
Result:

Induced no significant differences in body weight, suggesting good systemic tolerance.
Induced no apparent pathological abnormalities.
Exhibited attenuated tumor growth, showing notably stronger tumor inhibition than Gefitinib.
Triggered a marked reduction in Ki67 expression, indicating effective suppression of tumor cell proliferation.
Revealed no evident histopathological abnormalities.

Animal Model:

ICR mice (20 males and 20 females, 5-6 weeks)^[1]
Dosage:

12.5, 25, 50 mg/kg
Administration:

intragastric gavage (i.g.)
Result:

Induced no significant body weight loss.
Induced no apparent pathological abnormalities.

Chemical Information

Appearance Solid
Molecular Weight 426.47
Formula C₂₅H₂₂N₄O₃
Color Light yellow to yellow
SMILES

COC1=C(OCC2=CC=CC=C2)C=C(N=CN=C3NC4=CC=C(NC(C=C)=O)C=C4)C3=C1
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 5.83 mg/mL (13.67 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.3448 mL

11.7242 mL

23.4483 mL

5 mM

0.4690 mL

2.3448 mL

4.6897 mL

10 mM

0.2345 mL

1.1724 mL

2.3448 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (279 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Zhao M, et al. A novel Quinazoline derivative exerts anti-tumor effects in non-small cell lung cancer through Wnt/β-catenin pathway inhibition. Bioorg Chem. 2025 Jun 15;160:108481. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.3448 mL	11.7242 mL	23.4483 mL	58.6208 mL
	5 mM	0.4690 mL	2.3448 mL	4.6897 mL	11.7242 mL
	10 mM	0.2345 mL	1.1724 mL	2.3448 mL	5.8621 mL

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Wnt/β-catenin-IN-6

Bioactive Compound Library Max

Bioactive Compound Library

Apoptosis Compound Library

Immunology/Inflammation Compound Library

JAK/STAT Compound Library

Kinase Inhibitor Library

MAPK Compound Library

PI3K/Akt/mTOR Compound Library

Protein Tyrosine Kinase Compound Library

Stem Cell Signaling Compound Library

Wnt/Hedgehog/Notch Compound Library

Anti-Cancer Compound Library

Autophagy Compound Library

Anti-Aging Compound Library

Differentiation Inducing Compound Library

Reprogramming Compound Library

Oxygen Sensing Compound Library

Glycolysis Compound Library

Pyroptosis Compound Library

Cytoskeleton Compound Library

Orally Active Compound Library

Glutamine Metabolism Compound Library

Anti-Alzheimer's Disease Compound Library

Neuroprotective Compound Library

Anti-Hepatitis C Virus Compound Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Parkinson's Disease Compound Library

Neurodegenerative Disease-related Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Transcription Factor-Targeted Library

Glucose Metabolism Compound Library

Anti-Liver Cancer Compound Library

Anti-Colorectal Cancer Compound Library

Antidepressant Compound Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Chemokine Compound Library

Cancer Stem Cells Compound Library

Pain-Related Compound Library

Mitochondrial Protection Compound Library

Antihypertensive Compound Library

Metabolic Enzyme Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Cytokine Inhibitors Library

Cell Death Library

Serine/Threonine Kinase Inhibitor Library

Extracellular Vesicles (EVs) Compound Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Radioprotector Library

MCE Bioactive Compound Library

Anti-Gastric Cancer Compound Library

Anti-Fibrosis Compound Library

Anti-Brain Cancer Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

Lactic Acid Metabolic Compound Library

High-Throughput Bioactive Compound Library

Anti-Rheumatic Arthritis Compound Library

Lactylation Compound Library

All Wnt Isoforms

All EGFR Isoforms

All ERK Isoforms

All COX Isoforms

All Akt Isoforms

All GSK-3 Isoforms

All Interleukin Related Isoforms

All JNK Isoforms

Biological Activity

Chemical Information

Solvent & Solubility